Does Rallies show Form 4 insider transactions for BIIB?

Yes. Rallies tracks BIIB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BIIB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIIB. It does not provide personalized investment advice.

BIIB (Biogen) Stock Analysis - Insider Trades

Biogen (BIIB) is a publicly traded Healthcare sector company. As of May 20, 2026, BIIB trades at $187.75 with a market cap of $28.33B and a P/E ratio of 20.20. BIIB moved -1.35% today. Year to date, BIIB is +7.16%; over the trailing twelve months it is +47.22%. Its 52-week range spans $110.04 to $205.97. Analyst consensus is buy with an average price target of $218.76. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BIIB stock inside the company?

Recent BIIB insider activity includes Murphy Nicole bought 3, Singhal Priya sold 2.66K, Singhal Priya sold 748, Singhal Priya sold 517, and Izzar Rachid sold 2.22K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BIIB Key Metrics

Key financial metrics for BIIB
Metric	Value
Price	$187.75
Market Cap	$28.33B
P/E Ratio	20.20
EPS	$9.35
Dividend Yield	0.00%
52-Week High	$205.97
52-Week Low	$110.04
Volume	668.76K
Avg Volume	0
Revenue (TTM)	$9.94B
Net Income	$1.37B
Gross Margin	75.49%

Recent BIIB Insider Trades

Murphy Nicole bought 3 (~$585.105) on Feb 12, 2026.
Singhal Priya sold 2.66K (~$531.55K) on Feb 9, 2026.
Singhal Priya sold 748 (~$134.12K) on Feb 2, 2026.
Singhal Priya sold 517 (~$69.05K) on Sep 2, 2025.
Izzar Rachid sold 2.22K (~$300.11K) on Jul 8, 2025.

Latest BIIB News

Biogen Acquires Apellis for $5.3B and Advances Tau Drug, Shares Jump 10% — May 15, 2026
Biogen drops after Phase 2 CELIA diranersen data, despite plan for Phase 3 — May 14, 2026
Biogen Completes $41-Per-Share Apellis Acquisition While Alzheimer’s Drug Misses Primary Endpoint — May 14, 2026
Biogen’s Apellis Acquisition Spurs SmallCap 600 Removal on May 14 — May 7, 2026
Bright Horizons, Remitly Join S&P SmallCap 600 as Apellis and Tri Pointe Exit — May 7, 2026

BIIB Analyst Consensus

26 analysts cover BIIB: 0 strong buy, 15 buy, 10 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $218.76.

Common questions about BIIB

Who is trading BIIB stock inside the company?: Recent BIIB insider activity includes Murphy Nicole bought 3, Singhal Priya sold 2.66K, Singhal Priya sold 748, Singhal Priya sold 517, and Izzar Rachid sold 2.22K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BIIB?: Yes. Rallies tracks BIIB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BIIB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIIB. It does not provide personalized investment advice.